










 





CyFolex (Key Therapeutics, LLC): FDA Package Insert

 







DrugInserts.com
Vaccines and Other Medical Materials



    


CyFolex: Package Insert and Label InformationBy Key Therapeutics, LLC | Last revised: 12 January 2017
CYFOLEX- cholecalciferol, folic acid, calcium carbonate and bovine type i collagen capsuleKey Therapeutics, LLC  Dietary Supplement Dispensed by Prescription.        Supplement Facts   Serving Size: 1 Capsule Servings per container: 30   Amount Per Serving:  % Daily Value        *  Daily Values (DV) not established.      Vitamin D3 (as cholecalciferol) 800 IU 200%   Folic Acid 1 mg 250%   Calcium (as calcium carbonate) 50 mg 5%   Cyplexinol® Nature’s BMP – a Complex Partially Hydrolyzed collagen and its associated proteins Including Bone Morphogenetic Proteins (BMPs) 300 mg  *    OTHER INGREDIENTS



cellulose, magnesium stearate, and silicon dioxide.
DESCRIPTIONCyFolex Capsules is an orally administered prescription folic acid supplement for the clinical dietary management of suboptimal nutritional status in patients where advanced folate supplementation is required, and nutritional supplementation for maintenance of good bone and cartilage health is needed.
CONTRAINDICATIONSThis product is contraindicated in patients with a known hypersensitivity to any of the ingredients.
WARNINGS AND PRECAUTIONSCyFolex Capsules should only be used under the direction and supervision of a licensed medical practitioner.
Use with caution in patients that may have a medical condition, are pregnant, lactating, trying to conceive, under the age of 18, or taking medications.
Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient. Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.
Pregnancy and LactationCyFolex Capsules is not intended for use in pregnant or lactating patients.
ADVERSE REACTIONSYou should call your doctor for medical advice about serious adverse events. To report adverse side effects or to obtain product information, contact Key Therapeutics, LLC, Naples FL 34102 at 1-888-981-8337.
DOSAGE AND ADMINISTRATIONUsual adult dose is 1 capsule once or twice daily or as prescribed by a licensed medical practitioner.
HOW SUPPLIEDCyFolex Capsules are supplied as light yellow capsules, printed with “100″ dispensed in a child-resistant bottle of 30ct. (70868-100-301)
   1  Key Therapeutics, LLC does not represent these product codes to be National Drug Codes (NDC). Product codes are formatted according to standard industry practice, to meet the formatting requirement by pedigree reporting and supply-chain control including pharmacies. STORAGEStore at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature.]
Protect from heat, light and moisture.  KEEP OUT OF THE REACH OF CHILDREN. 
Tamper EvidentDo not use if seal is broken or missing. Manufactured for: Key Therapeutics, LLCNaples, FL 34102MADE IN CANADA
Dispensed by Prescription.
Rev. 12/16
† This product is a prescription-folate with or without other dietary ingredients that – due to increased folate levels increased risk associated with masking of B12 deficiency (pernicious anemia) requires administration under the care of a licensed medical practitioner (61 FR 8760). The most appropriate way to ensure pedigree reporting consistent with these regulatory guidelines and safety monitoring is to dispense this product only by prescription (Rx). This is not an Orange Book product. This product may be administered only under a physician’s supervision and all prescriptions using this product shall be pursuant to state statutes as applicable. The ingredients, indication or claims of this product are not to be construed to be drug claims.
PRINCIPAL DISPLAY PANEL — 30 Capsule Bottle Label70868-100-30 
CyFolex Capsules 
KEY therapeutics
Dispensed by Prescription 
30 Capsules 
    (click image for full-size original)     CYFOLEX  cholecalciferol, folic acid, calcium carbonate, and bovine type i collagen capsule       Product Information   Product Type  Item Code (Source) NDC:70868-100   Route of Administration ORAL DEA Schedule          Active Ingredient/Active Moiety   Ingredient Name Basis of Strength Strength   CHOLECALCIFEROL (CHOLECALCIFEROL)  CHOLECALCIFEROL 800 [iU]   Folic Acid (Folic Acid)  Folic Acid 1 mg   CALCIUM CARBONATE (CALCIUM CATION)  CALCIUM CATION 50 mg   BOVINE TYPE I COLLAGEN (BOVINE TYPE I COLLAGEN)  BOVINE TYPE I COLLAGEN 300 mg        Inactive Ingredients   Ingredient Name Strength    .ALPHA.-CELLULOSE       MAGNESIUM STEARATE       SILICON DIOXIDE           Product Characteristics   Color YELLOW Score no score   Shape OVAL Size 15mm   Flavor  Imprint Code 100   Contains          Packaging   # Item Code Package Description Multilevel Packaging    1  NDC:70868-100-30 30 CAPSULE in 1 BOTTLE None            Marketing Information    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date   DIETARY SUPPLEMENT  01/09/2017        Labeler — Key Therapeutics, LLC
       (080318791)
      Revised: 01/2017 Key Therapeutics, LLC





Share this Drug Information

Facebook

Stumble!
Tweet
Google +1

Pin

Print
Tell a Friend
More…

Also by this Manufacturer

Additional medications in the ‘Vaccines and Other Medical Materials’ section by Key Therapeutics, LLC.
Or get Key Therapeutics, LLC product information by RSS.

Related Searches
Within the ‘Vaccines and Other Medical Materials’ section:

Brand names beginning with the letter ‘C’ (CyFolex).
Medications with generic name beginning with the letter ‘C’ (CHOLECALCIFEROL, FOLIC ACID, CALCIUM CARBONATE, and BOVINE TYPE I COLLAGEN).
Medication information from January 2017, newest first or January 2017, earliest first.

FDA MedWatch

Cyclobenzaprine HCl and Amantadine HCl by Apace Packaging: Recall – Potential MislabelingFri, 28 Jul 2017. Unintentional dosing with Cyclobenzaprine HCl may potentially lead to the development of life-threatening serotonin syndrome, and other serious adverse events.Sterile Drug Products by Cantrell Drug Company: Recall –  Lack of Sterility AssuranceTue, 25 Jul 2017. Administration of a drug product intended to be sterile that is not sterile could result in serious infections that may be life-threatening.

Trustworthy Health Information


This site complies with the  HONcode standard for trustworthy health information: verify here.

VetLabel.com
Our full Veterinary Products section for consumers and veterinary professionals is now available exclusively via VetLabel.com.
 









 






Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version














Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version














Silicon Therapeutics LLC - Who is raising money? | SEC filings of fundraisings and investments in hedge funds, startups and private equity companies















Who is raising money?











Silicon Therapeutics LLC  Funding details


Silicon Therapeutics LLC Industry: OtherCIK Number: 0001684095IRS Number: 999999999Address: 148 DEPOT ROAD  HARVARD 01451Phone number: 617-937-2300



Latest news
Silicon Therapeutics LLC raised $6,249,498 from 1 investor on 2016-10-31.



Silicon Therapeutics LLC Filings

DateFiling TypeOfferedSoldRemainingMin. investmentInvest. countExemption / Exlusions
2016-10-31New Form D$6,249,498$6,249,4980$0106b[SEC Filing]2016-09-26New Form D$250,000$250,0000$0106b[SEC Filing]
Silicon Therapeutics LLC raised $6,499,498 in total.



Directors and Executives of Silicon Therapeutics LLC
Key People in Silicon Therapeutics LLC:

Peiqi SunEric LiShaoQing JiangJingsong Wang
Similar companiesSilicon Clocks, Inc., SILICON KINETICS INC, SILICON VALLEY MEDICAL INSTRUMENTS INC, Silicon Solar Solutions, LLC, SILICON STORAGE TECHNOLOGY INC, Silicon Frontline Technology Inc, Silicon Genesis Corp, SILICON SPACE TECHNOLOGY CORP, Silicone Arts Laboratories, LLC, Silicon Valley Growth Syndicate Fund I, LP, Silicon Harbor Ventures L.P., Silicon Valley Funding Partners, LLC








Last visited companies: Gigya, Inc., Gigya, Inc., Gigya, Inc., Gulfstream Technologies Inc., HEALTH DIAGNOSTIC LABORATORY INC

								© whoisraisingmoney.com
Daily updated news about investment into startups, hedge funds and private equity companies.
















Silicon Therapeutics Company Profile




























































BioPortfolio
Biotech, Healthcare and Medical Resources































Advertisement

Topics


All Topics
Biotechnology
Biotech Business
Biotech Products
Cancer
Cardiovascular
Dermatology
Drug Discovery
Endocrinology
Gastroenterology
Immunology
Infectious Diseases
Mental Health
Neurology
Obstetrics
Orthopedics
Public Health
Respiratory
Rheumatology
Urology 
			Track topics on Twitter
Track topics that are important to you




Printed From BioPortfolio.com

Silicon Therapeutics Company Profile

15:43 EDT 28th July 2017 | BioPortfolio













News Articles
[1767 Associated News Articles listed on BioPortfolio]
Woody Sherman joins Silicon Therapeutics as chief scientific officer
Silicon Therapeutics (Silicon Tx), an integrated computational drug discovery company creating novel small molecule therapeutics for difficult to target proteins, has announced the appointment of Wood...
Silicon Therapeutics Announces Recipient of the First Open Science 
      Fellowship
Friday, May 26th 2017 at 8:57pm UTC BOSTON–(BUSINESS WIRE)– Silicon Therapeutics, an integrated computational drug discovery company creating novel small molecule therapeutics for diseases...
Silicon Therapeutics Appoints Todd J. Martinez, Ph.D to Scientific 
      Advisory Board
Thursday, June 29th 2017 at 7:00pm UTC Appointment strengthens focus on applying quantum mechanical methods to metalloprotein-targeted drug design BOSTON–(BUSINESS WIRE)– Silicon Therapeut...
Silicon Therapeutics  Announces Recipient Of The First Open Science Fellowship
  Life Sciences Jobs                                               ...
Silicon Therapeutics Appoints Todd J. Martinez, Ph.D To Scientific Advisory Board
  Life Sciences Jobs                                                 ...
Woody Sherman Ph.D, Joins Silicon Therapeutics As CSO, Leading Efforts On Platform Development And Drug Design
  Life Sciences Jobs                                                 ...
Could alien life be made from silicon instead of carbon?

Hands-off approach to silicon chips
The possibility of looking inside silicon chips to see their tiny working parts, without damaging the chips, is a step closer thanks to an international team led by scientists at the LCN.


Drugs and Medications
[89 Associated Drugs and Medications listed on BioPortfolio]
Aldex [Pernix Therapeutics, LLC]
ALDEX GS™ Tablets
Aldex [Pernix Therapeutics, LLC]
ALDEX GS DMTablets
Pro-den rx [Zila Therapeutics, Inc.]
Pro-Den Rx
Pro-den rx [Zila Therapeutics, Inc.]
Pro-Den Rx
Pro-den rx [Zila Therapeutics, Inc.]
Pro-Den Rx


PubMed Articles
[867 Associated PubMed Articles listed on BioPortfolio]
Gamma radiation effects in amorphous silicon and silicon nitride photonic devices.
Understanding radiation damage is of significant importance for devices operating in radiation-harsh environments. In this Letter, we present a systematic study on gamma radiation effects in amorphous...
Compact focusing grating couplers for silicon horizontal slot waveguides.
In this Letter, we present the design, simulation (2D and 3D), fabrication, and experimental characterization of compact and fully etched focusing gratings for a horizontal slot waveguide based on a s...
Evaluation of porous silicon oxide on silicon micro-cantilevers for sensitive detection of gaseous HF.
Sensitive detection of harmful chemicals in industrial and environmental applications is pertinent to human safety. In this work, we demonstrate the use of a sensitive silicon micro-cantilever (MC) sy...
Enhanced optical magnetism for reversed optical binding forces between silicon nanoparticles in the visible region.
We perform a comprehensive numerical analysis on the optical binding forces of a multiple-resonant silicon nanodimer induced by the normal illumination of a plane wave in the visible region. The silic...
Quantification of the Void Volume in Single-Crystal Silicon.
This paper investigates the use of a method based on Cu decoration and neutron activation to determine the total volume of voids in a silicon single crystal. A measurement protocol was developed and t...


Clinical Trials
[130 Associated Clinical Trials listed on BioPortfolio]
Efficacy Study of Two Silicon-based Products to Treat Scars
This study aims to determine if a silicon-based gel and a silicon-based aerosol are
      effective in the treatment of postoperative scars.
Displacement Between PVC and Silicon DLT
The purpose of this study is to compare difference of displacement between Polyvinyl
      Chloride(PVC) and Silicon double-lumen endobronchial tubes(DLTs) during changing position
      from supine t...
Effects of Naturally Silicon-Rich Water on Bone Metabolism in Women
The aim of this research study is to determine by laboratory analyses the effects of
      drinking silicon-rich water on bone health.  This will be determined from blood and urine
      samples from ...
Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of silicon phthalocyanine 4 and
      photodynamic therapy in treating patients with stage IA-IIA cutaneous T-cell non-Hodgkin
      lymphoma....
Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a
      certain kind of light. When the drug is active, tumor cells are killed. Photodynamic therapy
      using s...


Companies
[1298 Associated Companies listed on BioPortfolio]
Silicon Therapeutics

Silicon Labs
Silicon Labs is an industry leader in the innovation of 
      high-performance, analog-intensive, mixed-signal ICs. Developed by a 
      world-class engineering team with unsurpassed expertis...
Silicon Biosystems, Inc.
Silicon Biosystems, Inc. was formed in October of 2010 as a wholly owned 
      subsidiary of Silicon Biosystems, S.p.A. based in Bologna, Italy. The 
      Company manufactures and sells the D...
Silicon Biosystems
Silicon Biosystems, S.p.A. is based in Bologna, Italy and has developed 
      a set of proprietary solutions called lab-on-a-chip technologies, 
      targeted at miniaturized cell-biology tes...
Focal Therapeutics
Focal Therapeutics is a medical device company based in Silicon Valley. 
      The companyâs first product is the BioZorbâ¢ tissue marker, a 
      bioabsorbable device that provides r...

More Information about "Silicon Therapeutics" on BioPortfolio
We have published hundreds of Silicon Therapeutics news stories on BioPortfolio along with dozens of Silicon Therapeutics Clinical Trials and PubMed Articles about Silicon Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Silicon Therapeutics Companies in our database. You can also find out about relevant Silicon Therapeutics Drugs and Medications on this site too.





Quick LinksAdvanced Search |
					Login |
					Subscribe | 
					RSS 

Quick Search






Advertisement


 

Corporate Database Quicklinks
Search Corporate Database
Latest Corporate Records
Biotech Companies by Location
Popular Company Records
Recent Company Searches
Add or Control Your Corporate Profile


Searches Linking to this Company Record


















BioPortfolio Limited

About Us
Contact Us

Social Media

Twitter (200+ Accounts)
Twitter 
Google+ 
LinkedIn 



Publish Content

Publish
Publish Your Press Release
Advertise

Agreements

Agreements
Medical Disclaimer
Privacy



Tools

MyBioPortfolio
RSS

Help

FAQs
Sitemaps
XML Sitemap







			This site complies with the
			HONcode standard for trustworthy health
			information:
Verify here.



		The information provided by BioPortfolio.com is not a substitute for
		professional medical advice, diagnosis or treatment. The BioPortfolio
		site is sponsored BioPortfolio Limited with offices at Stafford House,
		10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you
		are a legal copyright holder or a designated agent for such and you believe a
		post on this website falls outside the boundaries of “Fair Use” and
		legitimately infringes on your or your client's copyright we may be contacted
		concerning copyright matters at: priority@bioportfolio.com.
		
		All rights reserved. All other trademarks recognized. Copyright
		© 1997-2017 BioPortfolio Limited. Site developed by
		Alacrify Ltd.
	



































 



 Dermata Therapeutics, LLC Closes a $5 Million Series 1a Financing and Secures a $5 Million Credit 
         










    










 













 











 



















Dermata Therapeutics, LLC Closes a $5 Million Series 1a Financing and Secures a $5 Million Credit Facility with Silicon Valley Bank
        																																												
              
















 News provided by
Dermata Therapeutics, LLC  
Feb 16, 2017, 09:00 ET









 Share this article




























































SAN DIEGO, Feb. 16, 2017 /PRNewswire/ -- Dermata Therapeutics, LLC, a biotechnology company developing new and innovative products to treat a variety of dermatological diseases, today announced it has completed a $5 million Series 1a financing and entered into a $5 million credit facility with Silicon Valley Bank (SVB).  Dermata intends to use the capital for general corporate purposes to further Dermata's mission of making major advancements in the treatment of serious diseases treated by dermatologists.  








"We believe this funding strategy will provide us with the necessary capital to complete our two ongoing Phase 2 clinical studies with our lead candidate DMT210 in atopic dermatitis and rosacea. Moreover, it aligns us with a premier partner in SVB, helping us manage our cost of capital moving forward and providing the opportunity for significant value creation for our unit holders," states Gerald Proehl, President and CEO of Dermata.  
Dermata received $2.5 million at closing and, under the terms of the agreement, will receive an additional $2.5 million later this year, subject to achievement of certain specified milestones. 
About Dermata: Dermata is a development-stage biotechnology company focused on making major advancements in the treatment of serious diseases treated by dermatologists. Dermata has an experienced team who are currently focused on progressing four programs for the treatment of acne rosacea, atopic dermatitis, acne vulgaris and ocular rosacea.  To learn more about Dermata and its pipeline of treatments, please visit www.dermatarx.com.




 CONTACT:  
 Dermata Contact 




 Sean Proehl 




 Investor Relations 




 858.223.0882 




 sproehl@dermatarx.com 





 
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dermata-therapeutics-llc-closes-a-5-million-series-1a-financing-and-secures-a-5-million-credit-facility-with-silicon-valley-bank-300408534.html
SOURCE Dermata Therapeutics, LLC
 Related Links

http://www.dermatarx.com



 

















Apr 13, 2017, 08:00 ET
Preview: Dermata Therapeutics, LLC and Villani, Inc. Announce a Global License Agreement for a Natural Sponge Product for Skin Diseases




















Jan 18, 2017, 12:00 ET
Preview: Dermata Therapeutics, LLC Announces Initiation of Treatment in a Phase 2 Acne Rosacea Clinical Study








My News


  Release contains wide tables.	  View fullscreen.





 Also from this source




 











Apr 13, 2017, 08:00 ET
                                  				                                                                                     
                              Dermata Therapeutics, LLC and Villani, Inc. Announce a Global...






 Explore
 More news releases in similar topics

  Biotechnology
  Health Care & Hospitals
  Medical Pharmaceuticals
Financing Agreements








 You just read:
Dermata Therapeutics, LLC Closes a $5 Million Series 1a Financing and Secures a $5 Million Credit Facility with Silicon Valley Bank


 News provided by
Dermata Therapeutics, LLC  
Feb 16, 2017, 09:00 ET








 Share this article









































 











Looking to send a news release with PR Newswire?
Take advantage of the world's leading distribution platform.
Sign up to get started
Request more information
Have an account? Log In

















Search











Searching for your content...









Advanced Search












































 













 













Woody Sherman | Silicon Therapeutics LLC | Email @silicontx.com 











































LOGIN

7 DAY FREE TRIAL


























Woody Sherman

 Silicon Therapeutics LLC  CSO


Updated On : 
                    Mar 27, 2017                            

export

















300 A Street

Boston, MA 02210


Email format for @silicontx.com

Direct Phone: Not Available 









Type:

                    Private                
Employees: 
20 - 49

Revenue:  
Not Available

Industry:  
                        Biotech/Healthcare                    
SIC Code:  
                         2836  - Biological Products, Except Diagnostic








 BIOGRAPHY

 
                    If you need @silicontx.com email addresses for Silicon Therapeutics LLC, you can find them on Lead411 as Woody Sherman's email might be available. Woody Sherman, the company's CSO, also has extensive contact information, including Silicon Therapeutics LLC's facebook account, phone numbers, linkedin url, wiki, and biography. Boston, MA-based Silicon Therapeutics LLC can be found on Lead411 under the Biotech/healthcare industry.  Some possible email formats for Woody Sherman are WSherman@silicontx.com, Woody.Sherman@silicontx.com, Woody@silicontx.com, and Woody_Sherman@silicontx.com. If you sign up for our free trial you will see our email@silicontx.com addresses.            


Similar People:
Woody Sadler - Other
A , -based organization, VMI is just one of the many Lead411 profiles that you can find contact information, like phone numbers and emails. Their profile includes @vmivans.com email addresses, as well as details on Woody Sadler's email, the organization's Adjunct Professor. Their profile can be found in Automotive/transportation category. If you also need twitter, facebook, linkedin, wiki, and biography details for Woody Sadler, you can also find them in Lead411.  Some possible email formats for Woody Sadler are WSadler@vmivans.com, Woody.Sadler@vmivans.com, Woody@vmivans.com, and Woody_Sadler@vmivans.com. If you sign up for our free trial you will see our email@vmivans.com addresses.
Woody Saiyed - Other
Located in Langley,  East Berkshire College has Woody Saiyed serving as the organization's Numeracy Lecturer. Need Woody Saiyed's email, linkedin, phone numbers, facebook, wiki and biography? You can find essential contact information in East Berkshire College Lead411 profile, along with their East Berkshire College email addresses using the domain. Search for East Berkshire College on Lead411 under the Education/training industry.  Some possible email formats for Woody Saiyed are WSaiyed@eastberks.ac.uk, Woody.Saiyed@eastberks.ac.uk, Woody@eastberks.ac.uk, and Woody_Saiyed@eastberks.ac.uk. If you sign up for our free trial you will see our email@eastberks.ac.uk addresses.
Woody Salge - Executive
Woody Salge is part of DCP Midstream, an organization which has its main offices in Denver, CO.  Woody serves as the Field Manager at DCP Midstream.  If you're searching for DCP Midstream email addresses, you can also find those on their Lead411 profile with the domain @dcpmidstream.com along with Woody Salge's linkedin name, twitter tweets, wiki, phone numbers, and biography.DCP Midstream's Lead411 profile is categorized under the Oil, gas, coal industry.  Some possible email formats for Woody Salge are WSalge@dcpmidstream.com, Woody.Salge@dcpmidstream.com, Woody@dcpmidstream.com, and Woody_Salge@dcpmidstream.com. If you sign up for our free trial you will see our email@dcpmidstream.com addresses.


People Directory > Woody Sherman

















